Pipeline

Overview

DISCOVERY
PRECLINICAL
PHASE 1
PHASE 2
DT-101
Major Depressive Disorder (MDD)

DT-101 is a next-generation small molecule AMPA receptor positive allosteric modulator (PAM) aiming to deliver a transformative, ‘best-in-disease’ product profile in MDD.

DT-101 has been designed with a much wider therapeutic window compared to previous generation AMPAR PAMs to allow effective modulation of the AMPA receptor without compromising safety and tolerability.

DT-101 will enter Phase 2 studies in 2025.

DT-201
Neuropsychiatry (undisclosed)

DT-201 is a novel, highly selective negative allosteric modulator (NAM) of α5-GABAA receptors with best-in-class therapeutic potential for several neuropsychiatric disorders.

DT-201 is planned to enter Phase 1 safety and proof-of-mechanism studies in 2026.

DT-301
Neuropsychiatry (undisclosed)

DT-301 is a novel, highly selective α2/α3-GABAA receptor positive allosteric modulator (PAM) designed to deliver a best-in-class safety and tolerability profile.

DT-301 has strong therapeutic potential for a range of neuropsychiatric disorders that affect vulnerable patient populations, such as elderly or paediatric patients by avoiding α1 and α5-GABAA receptors, which trigger limiting side effects such as sedation, addiction and cognitive dysfunction.

DT-301 is planned to enter Phase 1 safety and proof-of-mechanism studies in 2026.

DT-101 | Phase 1
Major Depressive Disorder (MDD)

DT-101 is a next-generation small molecule AMPA receptor positive allosteric modulator (PAM) aiming to deliver a transformative, ‘best-in-disease’ product profile in MDD.

DT-101 has been designed with a much wider therapeutic window compared to previous generation AMPAR PAMs to allow effective modulation of the AMPA receptor without compromising safety and tolerability.

DT-101 will enter Phase 2 studies in 2025.

DT-201 | Preclinical
Neuropsychiatry (undisclosed)

DT-201 is a novel, highly selective negative allosteric modulator (NAM) of α5-GABAA receptors with best-in-class therapeutic potential for several neuropsychiatric disorders.

DT-201 is planned to enter Phase 1 safety and proof-of-mechanism studies in 2026.

DT-301 | Preclinical
Neuropsychiatry (undisclosed)

DT-301 is a novel, highly selective α2/α3-GABAA receptor positive allosteric modulator (PAM) designed to deliver a best-in-class safety and tolerability profile.

DT-301 has strong therapeutic potential for a range of neuropsychiatric disorders that affect vulnerable patient populations, such as elderly or paediatric patients by avoiding α1 and α5-GABAA receptors, which trigger limiting side effects such as sedation, addiction and cognitive dysfunction.

DT-301 is planned to enter Phase 1 safety and proof-of-mechanism studies in 2026.